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Abstract
COVALENT BINDING AND OTHER MECHANISMS OF PRIMAQUINE TOXICITY
by
Lucille S. K. Chau Yau
A dose-dependent covalent binding of primaquine to mouse liver 
microsomal protein was found in both in vitro and in vivo studies.
The binding in vitro was linear during the first 90 minutes of incu­
bation and dependent on the concentration of mouse liver microsomal 
protein. The in vitro covalent binding was markedly enhanced by co­
factors. Pretreatment of mice with phenobarbital, a cytochrome P450 
inducer, increased the microsomal cytochrome P450 content and the in 
vitro covalent binding significantly. Binding was markedly inhibited 
when microsomal metabolism inhibitors (SK&F-525A, metyrapone and 
piperonyl butoxide), and sulfhydryl-contai ni ng compounds were added 
to the incubation system. Conversely, the inhibitory effect of 
inhibitors was not shown on in vivo binding; also induction with pheno­
barbi tal decreased the extent of covalent bindi ng in vivo. These 
findings pointed to the possibility that the extent of in vivo forma­
tion of metabolites which can bind covalently may be limited. However, 
injection of PQ (80 mg/Kg) into mice decreased the glutathione content 
of liver and erythrocytes, possibly through the formation of reactive 
metabolites.
The NADPH-induced peroxidation of lipid of mouse mi crosomes and
human erythrocyte membranes were markedly inhibited by PQ and 5H6DPQ 
(a PQ derivative), respectively. In contrast, PQ and its derivatives
enhanced the NADPH-i nduced peroxidation of the lipids of intact
erythrocytes.
A significant amount of PQ metabolite(s) (formed by the mouse 
liver microsomal cofactor system) was bound covalently to the total
protein of both normal and G6PD-deficient erythrocytes.. The net bind­
ing to the protein of G6PD-defi ci ent red cells was significantly 
greater than that to normal cells. A measurable amount of covalent 
binding of PQ metabolite(s) to human hemoglobin was also demonstrated. 
A small but significant amount of PQ metabolite(s) was also bound to 
human erythrocyte membrane protein. PQ and its derivatives decreased 
the amount of measurable sulfhydryl groups of G6PD-defi ci ent human 
erythrocyte membranes significantly but had no effect on the -SH 
groups of normal cell membranes. These results suggest that covalent 
binding of PQ metabolite(s) to human erythrocyte total protein and 
membrane protein as well as to hemoglobin may play an important role
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CHAPTER 1: GENERAL INTRODUCTION
Glucose-6-Phosphate Dehydrogenase Deficiency
The occurrence of a deficiency of the enzyme glucose-6-phosphate 
dehydrogenase (G6PD) in human erythrocytes was discovered during 
investigations in Chicago (Carson et aj_. , 1956) of acute hemolytic 
anemia which occurred in about 10% of American Negroes after adminis­
tration of the 6-methoxy-8-ami noqui noli ne antimalarial drug, prima­
quine (PQ). This was 30 years after the first reported case of
hemolysis induced by the related drug, pamaquine.
G6PD is the first enzyme in the pentose phosphate pathway (PPP). 
It catalyzes the oxidation of glucose-6-phosphate to 6-phospho- 
gluconolactone by NADP, which is reduced to NADPH. This is the main 
regulatory step of the PPP. Approximately 10% of glucose-6-phosphate 
is metabolized by the PPP in normal, unstressed erythrocytes, while 
the other 90% is metabolized by the Embden-Meyerhof pathway of 
anaerobic glycolysis (Murphy, 1960).
G6PD-deficient erythrocytes have a diminished G6PD activity and 
other related metabolic abnormalities (Tarlov, et al., 1962; Carson and
(1) Abnormalities of the pentoseFrischer, 1966; Beutier, 1978):
phosphate pathway: pentose phosphate metabolism is deficient; NADPH 
regeneration capacity is impaired; reduced glutatione (GSH) content 
is reduced and GSH is more vulnerable to oxidation; glutathione 
reductase activity is increased due to a compensatory mechanism or a 
younger erythrocyte population; 0^ consunption is reduced and rate of
2
glucose utilization is diminished; lipid content is decreased; rate of 
methemoglobin reduction is diminished; methemoglobinemia is increased 
and cells are more susceptible to Heinz body formation; (2) Abnormali­
ties of Embden-Meyerhof Pathway: increased aldolase activity; 
decreased NADPH/NADP ratio and fall in ATP content in vitro;
(3) Diminished catalase activity.
Besides the biochemical abnormalities in G6PD-deficient
erythrocytes, Afolayan (1979) found that the reactivity of lipids and 
proteins of normal red cell (G6PD A) membranes, preincubated with PQ 
or chloroquine with tri nitrobenzene sulphonate, is less than that of 
G6PD-defi ci ent red cell (G6PD A-) membranes. The fluorescence studies 
in the presence of PQ or chloroquine also suggested a possible 
structure difference between the two types of ghosts.
The severity of hemolysis that occurs after ingestion of certain 
hemolytic drugs, chemicals, or plants is influenced by the concentra­
tion of drug in the blood; viral and bacterial infections; diabetic 
acidosis; hypoglycemia of the newborn; age of the erythrocytes and 
schedule of drug administration (Tarlov et aj_., 1962).
The deficiency in G6PD activity may be caused by decreased 
synthesis of enzyme molecules, reduced stability of enzyme molecules, 
decreased catalytic activity, the absence of activators or coenzymes 
essential for G6PD activity, the presence of inhibitors, or a combina­
tion of two or more of these mechanisms (Tarlov et_ al. , 1962; Carson
and Frischer, 1966; Beutler, 1969, 1982).
Until 1982, about 147 variants of G6PD have been characterized
3
(Beutler, 1982) according to the criteria set forth by the World 
Health Organization scientific group: 
electrophoretic mobility in different buffers; (3) the Michaelis 
constants for its substrates, glucose-6-phosphate and NADP; (4) 
capacity to utilize 2-deoxy glucose-6-phosphate, galactose-6- 
phosphate, and deamino NADP and NAD; (5) heat lability; and (6) pH 
optimum.
(1) red cell G6PD activity; (2)
G6PD B is the normal enzyme and is the most common type with a 
The most common types of G6PD deficient 
variants found in human erythrocytes are G6PD A, with 84% of normal
half life of 63 days.
enzyme activity; A-, with 5 to 15% of normal enzyme activity; Canton, 
with 0 to 5% of normal enzyme activity; and Mediterranean, with almost
no enzyme activity in mature erythrocytes (Haut, 1980).
G6PD deficiency in the Caucasian and Oriental is more severe than
that in the Negro. Hemolysis can be produced by very mild oxidant
stress in patients with the Mediterranean type variant. A small
number of G6PD-deficient subjects have a very rare variant. They show
the clinical picture of nonspherocytic congenital hemolytic anemia, 
but they experience hemolytic anemia in the absence of exposure to any 
stress (Beutler, 1969; Tarlov et al., 1962).
G6PD-deficiency has a world-wide distribution. The incidence
is highest in tropical and semi-tropical areas. The geographic 
distribution of this most common red cell enzyme deficiency tends to
parallel the occurence of Plasmodium falcipariun malaria. Moreover,
G6PD-deficient erythrocytes are less frequently parasitized than
4
normal red cells in vitro (Luzzatto et al., 1969). The frequency of
the deficient gene is approximately 10% among American Negroes 
(Hockwald et al_. , 1952), 5.5% among Southern Chinese (Chan et al. , 
1964) and a high incidence among Southern Mediterranean people 
(Szeinberg et jil_., 1958).
Europe.
Seldom are cases reported from Northern
The geographic distribution of G6PD-deficiency suggests an 
selective evolutionary advantage against malaria (Allison and Clyde, 
1961). GSH (Trager, 1941; Friedman, 1979) and the PPP (Trager, 1941) 
are essential for optimum growth of malaria parasites. The low GSH 
content and the diminished PPP activity of G6PD-deficient erythrocytes
are not adequate for survival of the invading parasites.'When sera.
collected from normal subjects at certain times after ingestion of a
meal of fava beans, were added to cultures of P. falciparum in normal,
G6PD-deficient, or 3-thalassemia trait red cells, Friedman (1983)
discovered that some sera were inhibitory to parasites in variant
cells but not to those in normal red cells.
The recent study by Luzzatto et ll- (1983) indicated that 
Plasmodiun falciparum invades G6PD-defi cient erythrocytes 
(Mediterranean variant) normally in culture but maturation of 
intracellular parasites is delayed and impaired, especially if the red 
cells are under oxidative stress. An adaptive change on the part of
the parasites has been found since the invading parasites have a
normal behaviour in the next cycle in G6PD-defi ci ent erythrocytes. 
Childs et aj_. (1 958) reported that the structural gene for
5
The gene is located on the X-G6PD-deficiency is sex-linked, 
chromosome close to the locus for color blindness (Adam, 1961;
Sim’s cal co and Filippi, 1964). 
hemizygous male subjects (XY) and rarely in homozygous females (XX). 
Heterozygous female subjects (XX) have one cell population with normal 
enzyme activity and another population with deficient activity
Therefore, the phenotype activity is either normal, 
intermediate, or low as in homozygotes or hemizygotes (Tarlov et al. , 
Only one of the two X chromosomes present in each somatic cell 
of the female is active, the other one being inactivated (Lyon 
hypothesis).
Most G6PD-deficient individuals have no overt symptoms under 
normal conditions since there is enough G6PD activity to protect the
The gene can be fully expressed in
(Beutler, 1982).
1962).
However, when these subjectscells in the normal physiologic state, 
are under oxidant stress (exposed to certain drugs, chemicals or
plants), this deficiency increases the susceptibility of the red cells
to destruction.
Primaquine Metabolism
Primaquine (6-methoxy-8-(4-ami no-1-methylbutyl ami no)quinoline, 
PQ) is an antimalarial drug.
been shown to be toxic to some sensitive individuals with G6PD
PQ and other 8-ami noquinolines have
Despite the widespread use of the drug, thedeficient erythrocytes.
metabolism of PQ is not well understood.
Some possibilities were suggested by the early work on the
6
metabolism of pamaquine by Brodie and Udenfriend (1950). From studies 
in dogs, they speculated that there was formation of a 5-hydroxy 
metabolite which reversibly produced a quinonimine capable of 
oxidizing hemoglobi n to methemoglobi n. Josephson et aj_. (1951) 
isolated a quinone of pamaquine formed by chickens and suggested that 
this metabolite may be the active agent against the malaria parasites.
In early studies in man, Zubrod (1948) observed that the highest 
plasma concentration of unmetabolized primaquine in patients was 
reached after 6 hours, then fell rapidly to virtually zero after 24 
hours. Other investigators also found that PQ, pamaquine, and 
pentaquine underwent rapid biotransformation in the rhesus monkey 
(Hughes and Schmidt, 1950; Smith, 1956). Only relatively small amounts 
of the unmetabolized PQ were found in the urine (Smith, 1956). The 
plasma level of metabolites of PQ and pentaquine exceeded that of the 
parent compounds (Hughes and Schmidt, 1950).
More recently Baty et aj_. (1975) found rapid metabolism of PQ in 
man by measuring the PQ level in blood and the uri nary excretion after 
oral administration of PQ to male subjects. They found PQ in red 
cells but not in plasma extracts. Using gas chromatography and mass 
spectrometry, they found that PQ underwent N-dealkylation to form a 6- 
methoxy-8-ami noqui noli ne derivative.
In studying the tissue distribution of PQ in rat, Holbrook et al. 
(1981) showed that concentration of PQ metabolites exceeded that of PQ 
itself and that unmetabolized PQ had a relatively short half-life, 4.0 
hour in lung, 1.7 - 1.9 hour in blood, spleen, kidney and heart; and
7
1.2 hour in liver. The tissue concentrations of unmetabolized PQ at 3
lung > kidney, spleen,
3
They could not demonstrate any FI- 
labeled metabolite with the quinoline structure in either extracts of
hours after PQ injection were in the order:
liver > heart > brain > blood.
rat tissues or after the in vitro incubation of PQ with rat hepatic
microsomes in the presence of NADPFI under air.
The investigation of Strother et a/L (1981) in dogs given PQ 
indicated that the PQ is metabolized rapidly or distributed from the 
blood to other parts of the body. These investigators observed that 
four or five metabolites of PQ are present in the urine of dog within 
five hours after injection, some of which cause methemoglobi n forma­
tion in dog and normal or G6PD-deficient human erythrocytes. In these 
experiments, using thin-layer chromatography and comparing with model 
metabolites, Strother et aj_. (1981) identified 6-hydroxy-8-(4-amino-1- 
methyl butyl ami no)qui noli ne (6FIPQ), 5-hydroxy-6-methoxy-8- (4-ami no-1- 
methyl butyl ami no )qui noli ne (5FIPQ), and unmetabolized PQ from urinary 
extracts of dogs. There was about 46.1%, 9.5% and 19.7% of 5FIPQ, 6HPQ 
and PQ, respectively. Strother et _al_. (1983) identified unmetabolized 
PQ and 5,6-di hydroxy-8-(4-ami no-l-methyl butyl ami no )qui noline (5FI6DPQ) 
from an incubation mixture of PQ and mouse liver microsomes in the
presence of an NADPFI-generati ng system.
Recently, Baker ^t aj_. (1982) have identified a carboxylic acid 
metabolite (8-(3-carboxy-l-methylpropylamino)-6-methoxyquinoli ne) in 
plasma from rat after PQ intravenous injection using high-performance 
liquid chromatographic, gas chromatographic, and mass spectral
8
methods. They also found that the concentration of metabolites is 
higher than that of PQ itself in the plasma except for the first few
minutes after PQ injection.
Magon et a1_. (1981) reported that the various hemolytic responses 
among G6PD-deficient subjects to PQ and other hemolytic drugs may be 
due to the variation of hydroxylation of these compounds via the 
cytochrome-P450 mixed function oxidase system.
These findings suggest the possibility that metabolites of PQ are 
responsible for the therapeutic as well as the toxic effects of PQ.
In any event, it is important to identify the structure of PQ metabo- 
lite(s) which is responsible for the antimalarial and toxic effects. 
Modification of the structure of PQ and its metabolite(s) to develop a 
new drug with high therapeutic index and diminished hemolytic effect 
in sensitive subjects may improve malaria chemotherapy.
Mechanism of Hemolysis by Primaquine
In the decade of the 1950's, many investigators studied the 
hemolytic effect of PQ on sensitive subjects. The hemolysis was found
to be due to an intrinsic defect of the red cells of individuals
51Cr-labelled PQ-sensitive to PQ (Dern et _al_. , 1954a). Using 
sensitive erythrocytes, Dern jit jfL (1954b) found that the acute 
hemolysis after PQ administration in 9 daily doses of 30 mg base was 
self-limited; the blood counts returned to normal spontaneously even
when drug administration was continued. Except for the presence of 
Heinz bodies in the red cells of sensitive subjects just before and at
9
the beginning of hemolysis, Beutler et a/L (1954a) could not detect 
any significant differences between normal and sensitive cells either 
before or during PQ administration. These investigators (Beutler et
C Q
al., 1 95 4b) later discovered that Fe-labeled red cells from
sensitive individuals were insensitive to the hemolytic effect of PQ 
when they were 8 to 21 days old. However, when the age of these red 
cells exceeded one-half of their life span, they were rapidly 
destroyed by PQ and certain aniline derivatives. Red cells contain a 
variety of enzyme systems which catalyze a large number of metabolic 
processes. Concentrations of many enzymes and coenzymes are decreased 
as the red cells become older (Ponder, 1951). This suggested that a 
deficiency in one of the enzymes in older red cells may play a role in 
PQ sensitivity. Furthermore, Dern ^t aj_. (1955) reported that PQ
sensitivity was a manifestation of a multiple drug sensitivity. All 
the drugs they studied had oxidant properties. The studies of Beutler 
et aj_. (1955 ) indicated that PQ-sensitive erythrocytes carried on 
normal glycolysis but contained only about 60% of the normal amount of 
GSH. The finding by Carson _et _a1. (1956) that the PQ-sensitive cells 
were deficient in glucose-6-phosphate dehydrogenase (G6PD) activity 
provided the first evidence for an explanation of these findings. The 
decreased supply of NADPH from the pentose phosphate shunt can slow 
the regeneration of GSH from GSSG (Beutler, 1978).
On the basis of the previously reported studies on PQ metabolism, 
Tarlov et _al. (1962) suggested that the hemolytic effect of PQ may be 
due to an oxidant quinone, a degradative intermediate, which has
10
anti catalase effect. The quinone may undergo a reversible oxidation- 
reduction reaction and eventually be metabolized to a quinonimine.
Cohen and Hochstein (1964) found that PQ in high concentrations 
(1 mM) produced hydrogen peroxide and methemoglobin in normal erythro­
cytes. They proposed that this could be a mechanism for oxidation of 
GSH and ultimately hemolysis in G6PD-deficient erythrocytes. 
Internalization of the red cell membrane and formation of intracellu­
lar vacuoles were also observed after incubation of normal human
erythrocytes with high concentrations of PQ by Ginn, Hochstein and 
Trump (1969). They suggested that this morphological change in the 
red cell membrane led to reduction in surface area and was significant
in red cell destruction.
Following the lead of Brodie and Udenfriend (1948) with 
pamaquine, Fraser and Vesell (1968) found that metabolites formed from
PQ administered to dogs produced red cell damage and hemolysis; this 
was subsequently confirmed and extended by Strother et jf[. (1975 , 
Fraser and Vesell (1968) also found that 5,6-dihydroxy 
derivative of pentaquine and 5 ,6-di hydroxy-8-ami noqui noli ne were 
considerably more active than PQ in oxidizing reduced glutathione and 
producing methemoglobi n in both normal and G6PD-deficient human
1981).
erythrocytes. They suggested that metabolites of PQ rather than PQ
itself may be responsible for producing the damage to the red cell. 
Subsequently they (Fraser et al., 1971) also showed that these
compounds oxidized GSH more readily in an older population of G6PD- 
deficient cells (with low levels of G6PD) than in a younger population
11
of G6PD-deficient cells (with high levels of G6PD).
Another possibi 1 ity was raised by the finding of Wittles (1970) 
that modification of phospholipid metabolism in human red cell 
membranes could be produced by PQ. He suggested that this might be 
another possible mechanism in drug-induced hemolysis.
The production of superoxide radicals by high concentrations of 
primaquine has been recently reported by Sunmerfield and Tudhope (1978) 
and confirmed by Fraser et_ a1_. (1981). Hydrogen peroxide formed from 
the superoxide radical led to methemoglobin formation. Again Fraser 
et _al_. (1981) found that hydroxylated derivatives of PQ were much more
active than PQ in producing superoxide anion or hydrogen peroxide.
On the basis of some of the above experimental observations the
following possible events seem likely in the production of hemolysis
(1) PQ is con-by PQ administration in a G6PD-deficient individual: 
verted to reactive metabolites by the microsomal mixed-function 
oxidase system; (2) superoxide radicals or hydrogen peroxide produced
by PQ metabolites or its nonenzymatic degradation products, may 
mediate hemoglobin oxidation, glutathione oxidation, and oxidative 
damage to the erythrocyte membrane; (3) however the glutathione
peroxidase system may protect against cell damage by peroxide at the 
expense of reduced glutathione (Chance, Sies and Boveris, 1979); (4)
G6PD-deficient erythrocytes are less capable of restoring nonnal 
reduced glutathione content due to the limited activity of the pentose 
phosphate pathway (Carson et al. , 1956; Tarlov et aj_. , 1962); (5) 
disruption of the cell membrane structure may lead to electrolyte
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leakage and imbalances across the membrane (Judah _et _al. ,1970); (6) 
the damaged cells may then be eliminated by intravascular hemolysis or 
removed by the reticuloendothelial system.
As will be discussed in Chapter 2, recent studies with other
drugs suggest that covalent binding of reactive metabolites may play a 
significant role in many different forms of drug toxicity, 
will be discussed in Chapter 3, lipid peroxidation may be an important
Also, as
factor in damage to membranes by drugs. The investigations reported
here were undertaken in order to explore the possible role of these
two phenomena in the mechanism of the hemolytic effect of PQ in
relation to the current evidence sunmarized above.
CHAPTER 2: COVALENT BINDING OF PRIMAQUINE TO MOUSE LIVER MICROSOMES
Introduction
Primaquine (PQ, an 8-ami noqui noli ne, has been used widely in 
radically curative treatment of exoerythrocytic vivax malaria since 
It has long been known that after large doses (30 mg) of 
PQ or i n sensitive individuals, severe hemolytic anemia, leukopenia 
and methemoglobinemia may be produced.
Fraser and Vesell (1968) found that the mechanical, but not the
the 1940s.
osmotic, fragility of G6PD-deficient erythrocytes was increased more 
than that of normal erythrocytes by hydroxylated model metabolites of 
pentaquine and acetanilid. These compounds also increased the
methemoglobin content, decreased the reduced glutathione content and 
decreased the NADPH/NADP ratio more markedly in G6PD-deficient red
cells than in normal cells; PQ at the same concentration was much less
active.
Many drugs and foreign compounds can be converted in the animal 
body to inert or active metabolites. The liver is the major organ of
drug metabolism. Drugs are usually metabolized to more polar 
compounds which can be more readily excreted. However, chemically 
reactive metabolites may be formed which subsequently induce severe 
toxicities by uncoupling integrated biochemical processes in cells or 
by combining covalently with tissue macromolecules. Toxicities 
including hemolytic anemia, methemoglobinemia, mutagenesis, cellular
necrosis, hypersensitivity reactions, blood dyscrasias, and 
fetotoxicities, are known to be mediated by chemically reactive
13
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metabolites (Gillette et al., 1974).
A wide variety of chemicals with unrelated structures, such as 
N-alkyl-N-nitroso compounds, ethionine, urethane, polycyclic aromatic 
hydrocarbons, aromatic amines, 4-nitroquinoline N-oxide and 
2-acetyl ami nofl.uorene, can be converted to alkylating, arylating agents 
or reactive metabolites and react with crucial cellular macromolecules
(DNA, RNA or proteins). The subsequent covalent interaction of these 
compounds with tissue proteins may result in carcinogenesis (Miller
and Miller, 1947 , 1952 , 1966; Miller, 1970; Magee and Barnes, 1967; 
Farber, 1963).
Judah et a1_. (1970) suggested that the hepatic injury caused by
some hepatotoxins might be mediated by their chemically reactive 
metabolites which bind to tissue macromolecules covalently. Since 
then many investigators have found that acetaminophen as well as 
phenacetin is converted to toxic metabolites by hepatic microsomal 
enzymes. The metabolites depleted hepatic reduced glutathione and 
were covalently bound to tissue protein. The severity of hepatic 
necrosis paralleled the magnitude of covalent binding (Mitchell et 
al. , 1975). The hepatic toxicity of acetaminophen was enhanced by a 
liver microsomal enzyme inducer (phenobarbital) and decreased by 
microsomal enzyme inhibitors (piperonyl butoxide, SK&F-525A, cobaltous 
chloride) (Mitchell et cil_. , 1973a, b; Jollow et al_. , 1973; Potter et 
al. , 1973). Similar effects of enzyme inducers and inhibitors on the 
hepatic toxicity of carbon tetrachloride and chloroform (Judah et al. , 
197 0), acetylisoni azid; acetyl hydrazine and iproniazid (Nelson et
15
al_. , 1977) have also been reported.
It seems possible that chemically reactive metabolites of PQ 
could leave the liver after depletion of its reduced glutathione and
bind to red cell membrane protein covalently as do bromobenzene 
metabolites to lung and heart muscle tissue proteins (Reid et al_. , 
197 3).
In the investigation we are reporting here, we have tested the 
hypothesis that PQ metabolites formed by mouse liver microsomes may 
bind to microsomal protein covalently. We have also investigated the 
possible modification of this binding by inducers and inhibitors of 
microsomal enzymes. The possibility that formation of these 
metabolites may produce a decrease of mouse liver and erythrocyte 





Initiated primaquine ( H-PQ), labelled in the ring system, was 
obtained from New England Nuclear Corporation and recrystallized in
the laboratory with nonlabelled PQ to obtain a specific activity of 
^C-PQ was supplied by the Special Programme for 
Research and Training in Tropical Diseases of the World Health Organi­
zation. It was recrystallized with nonlabelled PQ to obtain a
0.137 mCi/mmol.
specific activity of 1.03 Ci/mmol. The purity of the radioactive 
compounds was greater than 90% as verified by thin layer chromatogra­
phy with methanol-benzene (2:1) on silica gel (Strother et aj_. , 1981).
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Primaquine diphosphate was purchased from Aldrich Chemical Company, 
Inc., Milwaukee, WI. Nicotinamide adenine dinucleotide phosphate 
(NADP), glucose-6-phosphate (G-6-P), glucose-6-phosphate dehydrogenase 
(Type XII) (G6PD), 1-cysteine HC1, glutathione (reduced form), pheno- 
barbital, hexobarbital and bovine serum albumin (Fraction V) were 
obtained from Sigma Chemical Company, St. Louis, MO. Magnesiun 
chloride (MgCl^.SH^O) was supplied by J. T. Baker Chemical Company,
Phi 1lipsburg, NJ. Beta-diethylaminoethyldiphenylpropylacetate hydro­
chloride (SK&F-525A) was supplied by Smith Kline and French 
Laboratories, Philadelphia, PA. Metyrapone (MTP) was a gift obtained 
from CIBA Pharmaceutical Co., Summit, NJ.; piperonyl butoxide (PPB)
All otherwas obtained from K & K Laboratories, Inc., Plainview, NY.
chemicals were of highest purity available.
Preparation of Microsomes
Male Swiss-Webster mice (Simonsen Laboratory, Gilroy, CA) weigh­
ing 22-27 g were given regular Purina Lab Chow and water ad 1 ibitun. 
They were killed by cervical dislocation, the livers were removed 
immediately, blotted on absorbent paper and placed in a volume of ice
cold 1.15% KC1-0.025 M Tris buffer, pH 7.35, equal to twice the weight
of tissue. Microsomes were prepared in the same buffer, as described 
by Peters and Strother (1971). The protein content was determined by 
the method of Lowry et aj_. (1951) using crystalline bovine serin 
albumin as the reference standard. Cytochrome P450 content was 
measured as described by Peters and Fouts (1970).
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Incubation Mixture
14C-PQ, in 0.25 M Tris buffer (pH 7.35),Initiated primaquine or
at concentrations indicated in "Results", was incubated at 37°C with
mice liver microsomes (10 mg) and 1.0 ml of 0.25 M Tris buffer
NADP (4 ymol),(pH 7.35) containing an NADPH-generating system:
G6P (25 ymol), MgCl^ (30 ymol), and G6PD (2 units), 
received 1.0 ml of 0.25 M Tris buffer (pH 7.35) only.
Control flasks
The fi nal
volume of incubation mixture was brought to 5.0 ml with 1.15% KC1- 
0.025 M Tris buffer (pH 7.35) and distilled water. The reactions were
carried out under air in a Dubnoff shaking incubator and were stopped 
by adding 1.0 ml of 10% trichloroacetic acid (TCA) at the desired
In some experiments, SK&F-525A, MTP, PPB, 1-cysteine HC1 ortime.
reduced glutathione (Tredger jit a]_. , 1981) at concentrations indi­
cated in "Results", was added to the incubation mixture to study their
effects on covalent binding of PQ to mice liver microsomes.
In some studies, microsomes were prepared from mice pretreated in 
With phenobarbi tal (60 mg/Kg i. p. twice daily in normal 
saline for 3 days) the mice were killed 24 hours after the last dose). 
SK&F-525A (50 mg/Kg i.p. in normal saline) was administered 40 minutes 
before sacrifice (Cook et ^1_. , 1954) while PPB (1 ,360 mg/Kg i.p. in 




Control mice received normal saline or corn oil for similar
Determination of Covalent Binding of PQ to Mice Liver Microsomes
The incubation mixtures were transferred to 13 ml centrifuge 
tubes and centrifuged at 500 x g (International Refrigerated Centri-
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fuge. Model PR6) for 15 minutes at room temperature. The supernatant 
was discarded, and the protein precipitate was resuspended in 3.0 ml
of 10% TCA and mixed on a Vortex shaker for 3 minutes. The tubes were
centrifuged again at 500 x g for 10 minutes, and the protein pellets 
were washed again with 3.0 ml 10% TCA. The protein was then 
resuspended in 2 ml 80% methanol, mixed for 3 minutes, centrifuged at 
1000 x g for 10 minutes at room temperature and the supernatant 
discarded. This extraction was repeated until no further radioactiv­
ity could be removed (Jollow et aj_. , 1973). In our experiments, we 
routinely extracted the precipitated protein 9 times with methanol 
even though 6 to 7 extractions were sufficient to remove all the 
reversibly bound radiolabel. The extracted microsomal protein was 
dissolved in 1.0 ml (IN NaOH) and an aliquot of 20 yl was added to 
10.0 ml Cytoscint scintillation cocktail (West Chem Products, San 
Diego, CA) and counted in a Beckman LS-250 scintillation counter for
radioactivity. To ensure that the radiolabel was bound to microsomal
protein and not to lipid, some samples were extracted 3 times with 2
ml hexane before extracting with 80% methanol.
In vivo Covalent Binding
Mice were sacrificed 60 minutes after receiving varying doses of
143H-PQ or C-PQ and microsomes were prepared as in the i n vitro 
studies. To 1.0 ml of each microsome homogenate, 2.0 ml of 10% TCA 
was added to precipitate the protein. The protein pellet was washed
twice with 10% TCA and extracted with 80% methanol for 9 times as
An aliquot of 100 yl was counted for radioactivity.described above.
In other experiments, covalent binding of PQ to microsomes from mice
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pretreated with phenobarbital, SK&F-525A, and PPB as described above
were also studied.
Primaquine Effects on Tissue Glutathione Levels
Mice were injected with PQ (80 mg/Kg, i.p.) and sacrificed by 
cervical dislocation at various times after PQ administration. Blood 
was collected by cardiac puncture with heparin as anticoagulant. The 
blood was centrifuged at 1000 x g for 15 minutes. An aliquot of the 
packed erythrocytes was transferred to a centrifuge tube and lysed 
with 10 times its volume of distilled water. Five percent trichloro­
acetic acid--0.02 M disodiun ethylenedi ami netetraaceti c acid solution 
(TCA-EDTA) in a volime equal to that of the original red cells was 
added. Livers were removed from the mice inmediately after cervical 
dislocation, rinsed in ice cold normal saline, blotted and weighed 
before transferring to homogenization tubes. A sufficient volume of 
TCA-EDTA was added to the liver to give a 20% w/v homogenate. The 
tissue was homogenized using a glass mortar and a motor driven teflon 
pestle. The homogenates and lysed red blood cells in TCA-EDTA were 
centrifuged at 1000 x g for 15 minutes, 0.4 ml of the protein free
supernatant was mixed with 4.55 ml of a 0.01 M sodium phosphate
The blood samples were filtered through Whatman No. 1 
To each solution, 0.05 ml of 0.01 M 5,5‘-dithiobis-(2-
buffer, pH 8.0.
fiIter paper.
nitrobenzoic acid( (DTNB, Ellman's reagent) in absolute methanol was
added and absorbance of the resultant yellow colored solution against 
a reagent blank was determined in a Gilford spectrophotometer at 412 nm 
within 2 minutes (Sedlak and Lindsay, 1968; Olson etaj_., 1980).
Control values were also obtained when no PQ was administered. Data
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were expressed as percentage of the control values. Glutathione 
(reduced form) was used as the reference standard.
Statistics
Data were expressed as mean ± S.E.M. The significance of the
differences between means was determined by Students' t-test. Statis-
tical differences were considered to be significant with p < 0.05.
Results
As can be seen in Figure 1, considerable covalent binding of 
tritiated compounds to mouse liver microsomes occurred when they were 
incubated with ^H-PQ. The reaction was linear for 90 minutes with or
without the presence of an NADPH-generating cofactor system. The
amount of binding in the absence of cofactors was subtracted from 
that in the presence of cofactors to provide the net covalent binding 
probably attributable to metabolite(s). There was a steady and highly 
significant increase in net binding of tritiated metabolites during 
the first 90 minutes of the incubation; the net binding began to
In the absence ofdecline slowly after 150 minutes of incubation, 
cofactors, PQ itself or spontaneous breakdown products of PQ apparent­
ly became bound to microsomal protein.
The amount of the net covalent binding of primaquine depended on 
the concentration of mouse li ver mi crosomal protein, as shown in
The net binding was linear up to a concentration of 10 mg 
protein per 5 ml of incubation mixture and then decreased with 20 mg
Figure 2.
Therefore, in studying the binding reactions, weprotein per 5 ml.
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routinely used a microsomal protein concentration of 10 mg in 5 ml of
incubation mixture.
The possibility that the radioactivity in the methanol-extracted 
microsomes was partially attributable to primaquine still dissolved in 
lipid was tested by extracting first with hexane, a relatively
As shown in Table 1, three extractions withnonpolar organic solvent, 
hexane followed by nine extractions by 80% methanol did not alter the
3
binding of radioactive material from H-PQ to the microsomes as compared
to that found with nine extractions with 80% methanol alone.
3
The effect of the concentration of H-PQ on the extent of co­
valent binding in the presence and absence of cofactors was studied. 
As shown in Table 2, covalent binding occurred to a virtually similar
3
extent with or without cofactors at a H-PQ concentration of 1 mM,
whereas at low concentrations of 0.001 mM or 0.01 mM, binding was 
increased significantly by the presence of the cofactors. This 
suggests that at these low concentrations of PQ the increase in cova­
lently bound compounds in the presence of cofactors was most probably 
due to metabolites of PQ. As shown in Figure 3, an approximately
3
linear relationship was found when the amount of H bound to the 
microsomal protein is plotted against the logarithm of the concentra­
tion of PQ in the incubation mixture over the range of 0.005 to 0.05 mM.
3
On the basis of these findings a concentration of H-PQ of 0.01 mM was 
used in most of the other studies reported here.
In order to further establish that the net binding was attribut­
able to metabolism of PQ in the presence of the NADPH-generating 
system, we studied the effects of an inducer of cytochrome P450 and
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inhibitors of its function. Using microsomes in which the cytochrome 
P450 content was increased 75% by phenobarbital pretreatment, net 
covalent binding i n vitro was enhanced markedly over a wide range of 
primaquine concentrations, as shown in Figure 4. On the other hand, 
when the cytochrome P450 inhibitors, SK&F-525A (0.1 mM) or metyrapone 
(1 mM), were added to the incubation mixture (as described in "Methods") 
the net covalent binding was inhibited almost completely (Figure 4).
3
These results indicate that the net covalent binding of H to micro­
somal protein was due to metabolite(s) of primaquine produced by the 
action of the microsomal mixed function oxidase in the presence of the 
NADPH-generating system.
Figure 5 shows a double-reciprocal plot of net covalent binding 
in vitro of H-PQ metabolite(s) to microsomes prepared from control
and phenobarbi tal pretreated mice. The kinetic parameters were 
determined by calculation. The apparent Michaelis constant (Km) for
both control and phenobarbital pretreated mice microsomes was 2.6 x
-510 M. The maximum velocity (V
_2was 1.1 x 10 nmoles/mg protein/minute while that for microsomes from
_2phenobarbi tal pretreated mice was 1.7 x 10 nmoles/mg protein/ 
minute. Phenobarbi tal pretreatment increased the rate of binding by 
almost 55% without changing the apparent 14n.
) for microsomes from control micemax
Due to the possible lability of tritiun on the PQ molecule, we 
C-PQ in some binding studies, 
binding of ^H-PQ is compared to that of
14 In Tables 3 and 4 thealso used
14C-PQ by control and pheno­
barbi tal-pretreated microsomes and also by microsomes in the presence
The binding was somewhat less, but notof SK&F-525A or metyrapone.
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14significant, with ^H-PQ than with
the presence of metyrapone; however the results were qualitatively
very similar. Since the supply of ^C-PQ was quite limited it was 
3
necessary to use H-PQ for most of the studies.
Piperonyl butoxide (PPB), another inhibitor of mi crosomal-drug 
metabolizing enzymes, also markedly inhibited the covalent binding of
3
H-PQ to mouse liver microsomal protein when it was added to the 
incubation mixture, as shown in Table 5. However,’ the j_n vitro
3
covalent binding of H-PQ to microsomes prepared from piperonyl 
butoxide (1360 mg/Kg, i.p.) or SK&F-525A (50 mg/Kg, i.p.) pretreated 
mice was only inhibited by 14% (Table 6) although there was a somewhat 
greater percentage decrease in cytochrome P450.
The effect of the sulfhydryl-containing compounds, cysteine and
3
glutathione, at a concentration of 1 mM, on covalent binding of H-PQ 
metabolites to mouse liver microsomal protein was also studied, with 
the results shown in Table 7. In these studies, covalent binding was
C-PQ except for the net binding in
measured in either the presence or the absence of G6PD in the cofactor
Glutathione decreased the binding in the absence of G6PD butmixture.
cysteine was without significant effect. In the presence of G6PD
extensive binding occurred in the controls but both reagents inhibited
the net covalent binding almost completely.
As shown in. Tables 8 and 9, it was possible to demonstrate bind-
3
ing of H-PQ to microsomal protein i n vivo, 
piperonyl butoxide was administered to mice intraperitoneally before
3
the H-PQ injection, there was no significant difference in covalent 




of SK&F-525A and piperonyl butoxide dramatically prolonged hexobarbi-
tal sleeping time in the mice indicating that these compounds indeed
3
Apparently the covalent binding of H-PQinhibited drug metabolism. 
in vivo may not involve metabolism.
3
Figure 6 shows a linear relationship between the dose of H-PQ 
and its in vivo covalent binding to mouse liver microsomes. At a dose
14C-PQ also bound covalently to microsomes to an extentof 10 mg/Kg,
However, the insimilar to that seen with the tritiated isotope.
14vi vo covalent binding of C-PQ to microsomes of phenobarbital pre­
treated mice was significantly less than that to microsomes of control 
In preliminary studies a similar phenomenon also occurred with 
different doses of ^H-PQ (data not shown).
mi ce.
Apparently increased
metabolism of PQ in vi vo may decrease covalent binding.
The possibility that reactive metabolites of PQ may oxidize GSH 
i n vi vo was examined by measuring the reduced glutathione content of 
mouse liver and erythrocytes after injection of 80 mg/Kg of PQ. 
Figure 7 shows that hepatic GSH was significantly depleted at 60 
minutes after the time of injection; the normal level of GSH was re-
The GSH content ofgained at 4 hours after primaquine administration.
erythrocytes was more markedly decreased than that of the liver after 
60 minutes and took 8 hours to return to normal after the primaquine 
injection, as shown in Figure 8.
Discussion
In terms of criteria used by previous investigators (JoHow et
25
al., 1973; Mitchell et al. , 1973a, b; Potter et al., 1973), the data
in Tables 1 and 2 and Figures 1 and 6 clearly show covalent binding of 
PQ to microsomal protein both in vitro and in vivo, 
the pre-extraction with hexane (Table 1) to decrease the binding found 
after extraction with methanol appears to rule out the possibility that
3
significant amounts of the bound radioactivity are due to H-PQ 
dissolved in the lipids of the microsomes.
The failure of
At a concentration of 0.01
mM PQ, the net binding of radioactivity due to the presence of the 
NADPH-generating system accounts for over 80% of the total binding, at 
least for the first 90 minutes of the incubation (Figure 1). Conver­
sion of PQ to reactive metabolites by the mixed function oxidase system
At higher concen-is the most obvious interpretation of this result, 
trations the net binding attributable to the presence of the NADPH- 
generating system decreased (Table 2); since PQ itself is relatively 
unreactive, nonenzymatic breakdown of PQ to reactive products probably 
accounts for the binding seen in the controls without cofactors.
The marked increase in covalent binding in vi tro to microsomes 
prepared from mice pretreated with phenobarbital and containing 
increased levels of cytochrome P450 (Table 3, Figures 4 and 5) also 
clearly points to the role of metabolite(s) in the covalent binding
(Mitchell et ai]_. , 1973a, b; Potter et _al_. , 1973). The marked decrease
of the net covalent binding produced by the addition of the mixed func­
tion oxidase inhibitors, SK&F-525A, metyrapone, and piperonyl butoxide 
(Mitchell et_ aj_. , 1973b) shown in Tables 4 and 5 and Figure 4, again 
supports the interpretation that metabolites play a major role in the 
process of covalent binding in vitro at low concentrations (0.01 mM)
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of PQ.
In contrast to the increased covalent binding seen in vitro,
phenobarbital pretreatment decreased covalent binding of PQ in vivo 
(Figure 6). McLean and Marshall (1971) reported that phenobarbital 
diminished rather than increased the carcinogenic effects of aflatoxin 
in rats. Benedict et aj_. (1973) suggested that it is possible that 
low levels of microsomal enzymes are sufficient for drug metabolism, 
whereas enhanced drug metabolism by inducers of drug metabolism 
enzymes may further convert some metabolites to inert derivatives. 
Another microsomal enzyme inducer, 3-methylcholanthrene (3-MC), has 
been found to potentiate acetaminophen-induced hepatic necrosis 
(Mitchell et aj_. , 1973a, b) but protect against carbon tetrachloride- 
induced (Suarez et ah , 1971) and bromobenzene-i nduced (Reid et al., 
1971) hepatic necrosis. It is probable that besides inducing meta­
bolic enzymes to produce more reactive metabolites and thus enhance 
toxicities, these inducers stimulate an alternate pathway of metabolism 
which may compete with the toxic route, or a detoxification one (such 
as conjugation) to convert the toxic metabolites to innocuous deriva­
tives. Such events may also account for our results with PQ in vivo.
Again, in contrast to the i n vitro results (Tables 4 and 5,
Figure 4), the effect of the inhibitors, SK&F-525A and PPB, on covalent 
binding in vivo was not significant (Tables 8 and 9) even though the 
cytochrome P450 mixed function oxidase was indeed inhibited, as shown 
by the prolongation of hexobarbital sleeping time. It is possible 
that the level of enzyme activity remaining i n vivo in the presence of 
inhibitors is sufficient to produce the relatively lower levels of
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covalent binding found in vivo. Also other in vivo detoxification 
pathway(s) may be inhibited, thus increasing the supply of reactive 
metabolite(s) of PQ which bind to microsomal protein. Alternatively, 
the binding in vivo in the presence of the inhibitors may be due to
reactive products formed from PQ by nonenzymatic processes.
Our data show that cysteine and glutathione almost completely 
inhibited the covalent binding of PQ metabolite(s) to mouse hepatic 
microsomal protein in vitro (Table 7). Thiol groups such as those of 
GSH can combine with reactive metabolites to form S-alkyl or S-aryl 
derivatives (Waley, 1966) thus protecting the thiol groups on tissue 
proteins against covalent binding. Administration of PQ to mice 
depleted liver and erythrocyte GSH levels (Figures 7 and 8) as would 
be expected if reactive metabolites are produced in vivo and react
with the GSH. This correlates well with the report by Fraser and 
Vesell (1968) that the GSH content of G6PD-deficient erythrocytes can 
be decreased by incubation with model metabolites of pentaquine. The 
time course of covalent binding to microsomes in vitro and depletion of 
GSH in vivo show interesting parallels (cf. Figures 1 and 7); studies
of the time course of covalent binding in vivo would be needed to
establish this relationship more closely. These results parallel
those of other investigators who have shown that sulfhydryl-containing 
compounds such as glutathione and cysteine prevent the arylation of 
hepatic macromolecules by toxic metabolites of acetaminophen in vitro 
and in vivo without inhibiting the metabolism of the drug (Jollow et 
al. , 1973; Mitchell et et. , 1973b; Tredger et_ aj_. , 1981), Further­
more, pretreatments that affected acetaminophen-induced hepatic
28
toxicity also altered the depletion of hepatic glutathione (Mitchell 
Olson et ail_. (1980) have shown that doxorubicin, a 
potent anti cancer drug, depleted GSH levels in mouse liver, erythro­
cytes and heart but induced only dose-dependent cardiotoxicity.
Even though our data indicate that PQ metabolite(s) and/or break­
down products can covalently bind to mouse liver microsomal protein
et al. , 1973b).
i n vivo as well as i n vitro, we are not aware of any evidence of
hepatic damage following administration of PQ. As suggested by 
Mitchell et aj_. (1975), many drugs can be converted to active metabo­
lites and become covalently bound to microsomal protein, but yet this 
fact does not necessarily predict the occurrence of toxi city i n vivo. 
However, we (Chau et al_. , 1983) have found that reactive products 
from PQ may covalently bind to erythrocytes, their membranes and 
hemoglobin, thus suggesting that covalent binding of such products could 
damage erythrocytes and thus play a role in PQ-induced hemolytic anemia
in G6PD-defi ci ent individuals.
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Covalent binding of 0.01 mM H-primaquine to mouse liver 
microsomes in vitro by extraction with hexane and 80% methanol or with
Table 1.
80% methanol alone
nmoles bound/mg protein/60 minutes5
Net BoundWith CofactorsNo Co factorsExtraction with
0.16 ± 0.010.04 ± 0.003 0.20 ± 0.01Hexane and 80% 
methanol
0.17 ± 0.030.04 ± 0.003 0.21 ± 0.0380% methanol
aValues shown are the mean and standard error of 3 to 4 experiments.
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Covalent binding of 0.001 mM to 1 mM ^H-primaqui ne (^H-PQ) 
to mouse liver microsomal protein in vitro with or without cofactors
Table 2.
nmoles bound/mg protein/30 minutes9
^H-PQ Concen. Net BoundNo Cofactors With Cofactors
0.14 ± 0.14 •2.11 ± 0.13 
0.55 ± 0.08b 
0.13 ± 0.002c 
0.03 ± 0.003c
1.98 ± 0.221 mM
0.37 ± 0.060.23 ± 0.030.1 mM
0.09 ± 0.0030.01 mM 0.03 ± 0.001
0.02 ± 0.0030.001 mM 0.01 ± 0.0003
Values shown are the mean and standard error of 3 to 5 experiments. 
^Significantly different from the binding without cofactors at
p < 0.010.
Significantly different from the binding without cofactors at 
p < 0.005.
Covalent binding of 0.01 mM radiolabeled primaquine to control and pheno-Table 3.
barbital pretreated mouse liver microsomal protei n i n vitro
nmoles bound/mg protein/30 minutes5
Net BoundWith CofactorsNo CofactorsForm of PQPretreatment




14 0.11 ± 0.01 
0.15 ± 0.01c 
0.20 ± 0.02c
0.16 ± 0.010.05 ± 0.01C-PQ
3H-PQ 0.19 ± 0.010.04 ± 0.001
14 0.24 ± 0.010.04 ± 0.02C-PQ
Values shown are the mean and standard error of 3 to 4 experiments.
^Mi ce received 60 mg/Kg of phenobarbi tal twice daily for 3 days and were sacrificed 
24 hours after the last dose. The cytochrome P450 content of control mice liver 
microsomes was 0.76 ± 0.004; of phenobarbital pretreated mice liver microsomes was 
1.58 ± 0.12 nmoles/mg protein.
Significantly different from control at p < 0.005.
CO
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Effect of 0.1 mM SK&F-525A and 1 mM metyrapone (MIR) on covalent binding ofTable 4.
0.01 mM primaquine (PQ) to mouse liver microsomal protein in vitro
nmoles bound/mg protein/30 minutes3
%
Inhi bi tionNet BoundWith CofactorsForm of PQ No Co factorsDrug
3h-pq 0.09 ± 0.03 
0.11 ± 0.01 
0.01 ± 0.001b 
0.01 ± 0.003b 
0.02 ± 0.02b 
0.002 ± 0.001b
0.13 ± 0.0020.03 ± 0.001Control
14 0.16 ± 0.010.05 ± 0.01C-PQControl
3H-PQ 91%0.03 ± 0.0020.02 ± 0.001SK&F-525A
14 92%0.05 ± 0.010.04 ± 0.01C-PQSK&F-525A
3H-PQ 83%0.08 ± 0.030.07 ± 0.01MTP
14 98%0.09 ± 0.010.09 ± 0.01C-PQMTP
aValues shown are the mean and standard error of 3 to 5 experiments. 
^Significantly different from control at p < 0.001
CO
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Effect of piperonyl butoxide (PPB) at 0.5 mM and 1 mM on covalent bind- 
ing of 0.01 mM H-primaquine to mouse liver microsomal protei n i n vitro
Table 5.
nmoles bound/mg protein/30 minutes9
1o
Net Bound Inhi bi ti onWith CofactorsNo CofactorsDrug




80%0.02 ± 0.001 0.04 ± 0.002PPB, 0.5 mM
83%0.03 ± 0.0010.02 ± 0.001PPB, 1 mM
aValues shown are the mean and standard error of 3 experiments. 




Effects of pretreatments on covalent binding of 0.01 mM H-primaquine to mouse 
liver microsomal protein in vitro
Table 6.
nmoles bound/mg protein/30 minutes3
t
Net Bound Inhi bi tionWith CofactorsNo Co factorsSource of Microsomes
Normal saline pretreated^
SK&F-525A pretreated0
Corn oi 1 pretreated^
Piperonyl butoxide 
pretreatede
0.07 ± 0.010.14 ± 0.020.07 ± 0.01
14%0.06 ± 0.010.13 ± 0.010.07 ± 0.01
0.10 ± 0.010.15 ± 0.010.05 ± 0.004
14%0.09 ± 0.020.12 ± 0.010.03 ± 0.002
aValues shown are the mean and standard error of 3 to 5 experiments.
^Control mice received 0.01 ml/gm of 0.9% NaCl (i.p.) 40 minutes before sacrifice.
P450 content was 0.7 9 ± 0.02 nmole/mg protein.
CSK&F-525A pretreated mice received 50 mg/Kg of SK&F-525A in 0.9% NaCl (i.p.) 40 minutes 
before sacrifice. Cytochrome P450 content was 0.67 ± 0.04 nmole/mg protein.
^Control mice received 0.01 ml/gm of corn oil (i.p.) 30 minutes before sacrifice.
P450 content was 0.84 ± 0.07 nmole/mg protein.
ePiperonyl butoxide pretreated mice received 1,360 mg/Kg of PPB in corn oil (i.p.) 30 minutes 






Effect of sulhydryl-contai ni ng compounds on covalent binding of 0.01 mM H-primaquine to 
mouse liver microsomal protein in vitro
Table 7.
nmoles bound/mg protein/30 minutes^
l
Net BoundCofactors With G6PD Inhi bi tionCofactors Without G6PDDrug
0.21 ± 0.02 0.15 ± 0.02
0.001 ± 0.002c 
0.02 ± 0.001d
0.06 ± 0.01Control
99%0.07 ± 0.020.07 ± 0.02Cysteine, 1 mM
88%0.05 ± 0.040.03 ± 0.003Glutathione, 1 mM
aThe cofactors were added to the incubation mixture 5 minutes after incubation started.
^Values shown are the mean and standard error of 3 experiments.
Significantly different from control at p < 0.001 
dSignificantly different from control at p < 0.05
COcn
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Effect of SK&F-525A on covalent binding of ^H-primaqui ne 
(80 mg/Kg) to mouse liver microsomal protein in vivo
Table 8.
nmoles bound/mg protein9Pretreatment
Controlb 0.06 ± 0.01
c,dSK&F-525A 0.04 ± 0.01
aValues shown are the mean and standard error of 3 experiments.
^Control mice received 0.01 ml/gm of 0.9% NaCl 40 minutes before 
3H-primaquine (80 mg/Kg) was injected and the mice were sacrificed 60 
minutes after PQ injection. The cytochrome P450 content was 0.85 ± 0.03 
nmole/mg protein.
CSK&F-525A pretreated mice received 50 mg/Kg of SK&F-525A in 0.9% NaCl 
40 minutes before ^H-primaquine (80 mg/Kg) was injected and the mice 
were sacrificed 60 minutes after PQ injection. The cytochrome P450 
content was 0.86 ± 0.02 nmole/mg protein.
^Hexobarbital sleeping time of SK&F-525A pretreated mice was significant­
ly longer than that of control at p < 0.001. Control mice slept 
43.0 ± 5.9 minutes and SK&F-525A pretreated mice slept over 24 hours.
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Effect of piperonyl butoxide (PPB) on covalent binding of
3
H-primaquine (80 mg/Kg) to mouse liver microsomal protein in vivo
Table 9.
nmoles bound/mg protein5Pretreatment
Control*3 0.06 ± 0.01
c,dPPB 0.07 ± 0.004
aValues shown are the mean and standard error of 3 experiments.
^Control mice received 0.01 ml/gm of corn oil (i.p.) for 30 minutes 
before ^H-primaquine (80 mg/Kg) was injected and was sacrificed 60 
minutes after PQ injection. The cytochrome P450 content was 0.83 ± 0.07 
nmole/mg protein.
cPiperonyl butoxide pretreated mice received 1,360 mg/Kg of PPB in corn 
oil 30 minutes before ^H-primaquine (80 mg/Kg) was injected and was 
sacrificed 60 minutes after PQ injection. The cytochrome P450 content 
was 0.24 ± 0.09 nmole/mg protein.
-i
Hexobarbital sleeping time of PPB treated mice was significantly longer 
than that of control at p < 0.001. Control mice slept 11.0 ± 2.5 
minutes and PPB pretreated mice slept 138.8 ± 13.6 minutes.
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3Time course of covalent binding of 0.01 mM H-primaquine toFi gure 1.
mouse liver microsomes. Each point is the mean and standard error of 
3 to 6 experiments. • 
ing without cofactors. (Each point is significantly different from 
binding with cofactors at the same incubation interval at p < 0.005.) 
o, net binding.
#, binding with cofactors; ■ ■ , bind-
o
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to mouse liver microsomal protein in vitro, 
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Figure 4. Effects of cytochrome P450 inducer and inhibitors on net 
covalent binding of 0.005 mM to 0.05 mM ^H-primaquine to mouse liver 
microsomal protein in vitro. Each point is the mean and standard error
of 3 to 5 experiments. O----- O, net binding to microsomes from control
mi ce;# 
mi ce;Q
presence of 0.1 mM SK&F-525A;B 
control mice in the presence of 1 mM metyrapone.
#, net binding to microsomes from phenobarbital pretreated 
□ , net binding to microsomes from control mice in the
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Figy
mM ^H-primaquine metabolites to control and phenobarbital pretreated 
mouse liver microsomal protein in vitro. Each point is the mean and 
standard error of 3 to 5 experiments, 
from control mice, Vmax =1.1 x 10~2 
binding to microsomes from phenobarbital pretreated mice, Vmax =1.7 x 
10“2 nmoles/mg protein/minute. Apparent ttn =2.6 x 10”^^ for both types 
of microsomes.
Lineweaver-Burk plot of covalent binding of 0.005 mM to 0.05re 5.
#, net binding to microsomes 
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3
Figure 6. Covalent binding of H-primaquine (10 mg/Kg to 80 mg/Kg) and 
l^C-primaquine (10 mg/Kg) to control and phenobarbital pretreated mouse 
liver microsomes in vivo. Control mice: cytochrome P450 content was 
0.76 ± 0.004 nmoles/mg protein, •^H-primaquine injected, n=3; A, l^C- 
primaquine injected, n=4. Phenobarbi tal pretreated mice (as described 
in "Methods") cytochrome P450 content was 1.81 ± 0.05 nmoles/mg protein, 

















oCvJ 00 CD CVJ
OO Oo
uigjojcI iBiuosoJOiiu 6uu/punoq S0|ouu u
50
Figure 7. Effect of 80 mg/Kg of primaquine on reduced glutathione 
(GSH) content of mouse liver in vivo. Each point is mean and standard 
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Figure 8. Effect of 80 mg/Kg of primaquine on reduced glutathione (GSH) 
content of mouse erythrocytes in vivo. Each point is mean and standard 






















•5 1 2 4 8
Hours, after PQ injection
Fig. 8
CHAPTER 3: COVALENT BINDING AND OTHER MECHANISMS OF
PRIMAQUINE TOXICITY IN HUMAN BLOOD
Introduction
It has long been known that when primaquine (PQ, an antimalarial 
drug) is administered to sensitive men, an acute hemolytic anemia 
develops (Hockwald et aj_. , 1952). However, the mechanism of this 
reaction is still not completely understood (Beutler, 1978).
Lipid peroxidation appears to play a significant role in drug- 
induced membrane damage. Liver microsomes undergo lipid peroxidative 
damage when they are incubated with NADPH. When erythrocytes were 
incubated with this peroxidative system, they hemolyzed (Rodgers et 
al., 1977). Many agents which deplete GSH in isolated hepatocytes 
also induce lipid peroxidation (Anundi ejt a1_., 1979). Doroshow et al. 
(1979) and Olson et aj_. (1980) reported that adriamycin decreased 
heart, liver and erythrocyte GSH levels and induced toxicity. 
Adriamycin treatment in rats inhibited microsomal cytochrome P450 and 
other enzymes activity; it also enhanced in vitro lipid peroxidation 
of liver microsomes by producing reactive oxygen species through its 
redox cycling and oxidized endogenous membrane a-tocopherol (Mimnaugh 
et jfl_. , 1981a, b). The protective roles of a-tocopherol, GSH, and 
other enzymatic defenses against radicals and oxidative damages are 
discussed by Fridovich (1978) and Chance ed: aj_. (1979).
Carbon tetrachloride is the best known compound which is con­
verted to trichloromethyl radical by microsomal enzyme and induces 
toxicogenic events. This specie binds to protein and lipid covalently
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(Reynolds, 1967) and also initiates peroxidation of membrane lipids 
(Recknagel and Glende, 1973). Other compounds which initiate toxic 
events through their radical metabolites are reviewed by Mason (1979) 
and Trush et jH. (1982).
The chain reactions of membrane lipid peroxidation disrupt mem­
brane structure integrity, and thus alter membrane-bound enzyme 
activities (van Boxten et aj_. , 1979; Wills, 1971), membrane permea­
bility (Hogberg et aj^., 1973), and finally increase membrane deforma- 
bility and induce membrane breakages (Pasquali-Ronchetti et _al_. , 1980).
Various drugs and foreign compounds have been found to be con­
verted in the body to chemically reactive metabolites that bind 
covalently to tissue macromolecules thereby causing toxicities (Miller 
and Miller, 1966; Miller, 1970; Magee and Barnes, 1967; Judah et al. , 
1970; Mitchell et_ al_. , 1975). The magnitude of covalent binding 
parallels the severity of toxicity (Mitchell ejb ll-, 1973a, b; Jollow 
et al. , 1973; Potter et aj_. , 1973), and parallels the depletion of GSH 
content (Mitchel1 et al., 1973b).
A sharp depletion of the GSH of G6PD-deficient red cells 
followed by acute hemolysis occur after administration of PQ to 
susceptible subjects (Flanagan et aj_. , 1958). This phenomenon empha­
sizes the importance of erythrocyte GSH for the maintenance of cell 
integrity (Fegler, 1952). Fraser and Vesell (1968a, b) found that 
hydroxylated metabolites of PQ, pentaquine, and acetanilid increased 
mechanical fragility and methemoglobin content but decreased GSH con­
tent in G6PD-deficient human erythrocytes more than that of normal
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Studies of Strother jit _al_. (1981 , 1983) also indicated thatones.
model metabolites of PQ, but not PQ itself, increased a dose-related
methemoglobin formation in normal and G6PD-deficient erythrocytes. 
These metabolites depleted GSH content of G6PD-deficient red cells, 
whereas normal erythrocyte GSH levels were also depleted by high 
concentrations of PQ model metabolites.
The importance of membrane sulfhydryl groups for the integrity of 
the red blood cells and for the maintenance of cellular enzymes activ­
ity have been demonstrated by some investigators (Rapport and Scheuch, 
1960; Scheuch et _al_. , 1961). The destructi bi lity of red cel Is might 
be due to the oxidation of their membrane sulfhydryl groups (Jacob and 
Jandl, 1962a, b). Szeinberg and Clejan (1964) reported that the 
protein sulfhydryl groups and GSH in whole blood cells of G6PD- 
deficient individuals were significantly lower than those of normal 
subjects. In contrast, there were no significant differences in the 
membrane sulfhydryl groups and GSH contents between the two kinds of 
red cells.
Previous work (Chau et al., 1983) has shown that PQ metabolite(s) 
depleted hepatic as well as erythrocyte GSH levels and were bound to 
mouse liver microsomal protein covalently.
generate reactive oxygen species (Cohen and Hochstein, 1964; Simmer- 
field and Tudhope, 1978; Fraser et al. , 1975, 1981 ). 
that PQ toxicity is mediated by lipid peroxidation of red cell 
membranes through reactive oxygen species or by covalent binding of 
its reactive metabolite(s) to red cell membranes, hemoglobin and other
PQ has also been found to
It is possible
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proteins after cellular anti oxidative and other defensive mechanisms 
are diminished (Bus and Gibson, 1979; Chance et aj_. , 1979).
In the investigation we are reporting here, we have measured the 
lipid peroxidation of mice liver microsomes and human erythrocytes as
well as their membranes by PQ and its model metabolites. Covalent
binding of PQ to human erythrocytes as well as their membranes and
Effects of a-tocopherol on lipid peroxi-hemoglobin has been studied.
dation, covalent binding and methemoglobin formation are reported.
The effect of PQ and its derivatives on sulfhydryl groups of normal 
and G6PD-deficient erythrocyte membranes was also determined.
Materials and Methods
Chemicals
Primaquine diphosphate (PQ) was obtained from Aldrich Chemical
H-PQ, labelled in the ring system, was 
purchased from New England Nuclear Corporation, Boston, MA, and re- 
crystallized in the laboratory with unlabelled PQ to obtain a specific 
activity of 0.137 mCi/mmol. The purity was over 90% as determined by 
thin layer chromatography (TIC) with methanol-benzene (2:1) on silica 
gel (Strother et aj_. , 1981). The 5-hydroxy-6-demethylprimaquine 
hydrobromide (5H6DPQ) was synthesized as described by Allahyari et al. 
(1983). The blue derivative of 5H6DPQ was prepared in the laboratory 
by extracting 5H6DPQ.3HBr in IN NaOH with methylene chloride. The 
extract turned blue upon exposure to sunlight. The blue compound was 
purified by TIC and its identity verified by mass spectrophotometry as
Company, Inc., Milwaukee, WI.
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described by Strother et_ aj_. (1983). 
tide phosphate (NADP), glucose-6-phosphate monosodi un salt (G6P), 
glucose-6-phosphate-dehydrogenase (G6PD), glutathione (reduced form), 
bovine serum albumin, himan hemoglobin (Type IV), a-tocopherol acid 
succinate, 2-thiobarbituric acid and 1,1,3,3-tetraethoxypropane were 
obtained from Si gna Chemical Company, St. Louis, MO. 
chloride was purchased from J. T. Baker Chemical Company, Phillips- 
Sephadex G-75 superfine was supplied by Pharmacia Fine 
Chemicals, Inc., Piscataway, NJ. 




CytoScint scintillation cocktail was
All other chemicals were of
highest purity available.
Preparation of Microsomes
Male Swiss-Webster mice, obtained from Simonsen Laboratories,
Gilroy, CA and weighing 22-27 g, were fed regular Purina Lab Chow and
They were killed by cervical dislocation, thewater ad libitun.
livers were dissected out immediately and the gallbladder and other 
extraneous tissue rapidly removed. The livers were then blotted on 
absorbent paper, quickly weighed, and placed in ice-cold 1.15% KC1- 
0.025 M Tris buffer, pH 7.35. A 33% suspension of microsomes, in the 
same buffer, was prepared as described by Peters and Strother (1971).
Preparation of 50% Hunan Erythrocyte Suspension and Erythrocyte
Membranes (GhostiJ
Blood specimens were obtained by venipuncture from normal and 
G6PD-deficient volunteers with disodium edetate as anticoagulant. 
50% washed erythrocyte suspension was prepared in 0.85% buffered
The
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saline containing 10 mM dextrose as described by Fraser and Vesell 
(1968a). Human erythrocyte ghosts were prepared from washed, packed 
cells by the method described by Fairbanks et aj_. (1971).
Protein content was measured by the method of Lowry et ah (1951) 
using crystalline bovine serin albumin as the reference standard. 
Hemoglobin concentration was determined by reading the absorbance (at 
540 nm) in cyanmethemoglobin reagent (Hycel Inc., Houston, IX) using 
human hemoglobin (Si gna Chemical Co., Type IV) as the reference 
standard.
Lipid Peroxidation
Mouse liver microsomes (1.75 mg), human erythrocytes (0.5 ml of 
50% RBC suspension), or human erythrocyte membranes (4.0 mg) were 
incubated alone or with PQ, 5H6DPQ, or the blue derivative of 5H6DPQ 
(at concentrations indicated in "Results") in the presence or absence 
of an NADPH-generating system (cofactors) in 0.5 ml 0.25 M Iris buffer 
(pH 7.35) containing NADP (3.3 ymol), G6P (35 ymol), MgCl^ (15 ymol), 
and G6PD (2 units). The blue derivative of 5H6DPQ was dissolved in 
methanol, placed in the incubation flasks and the methanol was evapo­
rated under a stream of prior to addition of any other materials. 
Tris buffer (0.25 M, pH 7.35) was added to bring the final volume of 
the incubation mixtures to 1.75 ml. Incubation was carried out at
37°C under air in a Dubnoff shaking incubator for varying times. Zero­
time blanks containing all the components of the incubation mixtures
In some experiments, a-tocopherol was added in awere also included.
small volume of absolute alcohol to produce a final concentration of
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0.01 mM. Lipid peroxidation was quantitated by spectrophotometric 
determination of the malondi aldehyde-thiobarbi turic acid complex 
(Bernheim et al., 1948). At the end of the incubation, 0.75 ml of 
cold 2.0 M TCA-1.7 M HC1 was added to each incubation flask. The
incubation mixtures were transferred to centrifuge tubes and centri-
To each 0.5 ml of the clear super-fuged at 1000 x g for 10 minutes, 
natant, 2.0 ml of 1.0% w/v 2-thiobarbituric acid reagent (Kohn and
Li versedge, 1944) was added and incubated at 95°C for 15 minutes and
The absorbance was measured at 533 nm on a Beckmancooled on ice.
Acta MVI UV-visible spectrophotometer. Standard malondialdehyde was 
prepared by the acid hydrolysis of tetraethoxy-propane.
Binding to Mouse Liver Microsomal Protein
•3
H-PQ was incubated with mouse liver microsomes, containing 
a-tocopherol in absolute ethanol or absolute ethanol, with or without
an NADPH-generating system in 1.0 ml 0.25 M Tris buffer (pH 7.35) 
containing NADP (4 ymol), G6P (25 ymol), MgCl^ (30 ymol) and G6PD 
(2 units). The incubation conditions and method of extraction of the 
mouse liver microsomal protein were previously described (Chau et al. , 
1983).
Binding to Human Erythrocytes
-3
H-PQ was incubated with 1.0 ml 50% human erythrocytes suspension 
and mice liver microsomes (10 mg) in the presence or absence of an
NADPH-generating system as described previously. After incubation at 
37°C for 60 minutes under air in a Dubnoff shaking incubator, the 
incubation mixtures were centrifuged at. 500 x g for 10 minutes. The
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supernatant was aspirated from the erythrocytes as much as possible. 
The bottom-most 0.3 ml of the packed erythrocytes was transferred to 
13 ml centrifuge tubes and lysed with 0.9 ml of distilled water. 
Absolute methanol (3.0 ml) was added to the lysed erythrocytes and the 
tubes were centrifuged again at 1000 x g for 10 minutes. The protein
pellets were extracted 3 times with 2 ml hexane and then 9 times with 
80% methanol as previously described (Chau et aj_. , 1983). The
extracted protein pellet was dissolved in 1.0 ml 10% sodiim dodecyl
sulfate and an aliquot of 20 yl was added to 10.0 ml CytoScint
scintillation cocktail. Radioactivity was determined in a Beckman LS-
250 scintillation counter.
Binding to Human Erythrocyte Membranes (Ghosts)
o
H-PQ was incubated with human erythrocyte membranes (4.0 mg) and 
mouse liver microsomes (10.0 mg) with or without an NADPH-generating
system. The protein was precipitated by 10% TCA and extracted as
described above.
Binding to Human Hemoglobin
A column (35 x 1.4 cm) of superfine Sephadex G-75 was packed in 
equilibriun with 0.05 M phosphate buffer, pH 7.8, containing 0.15 M 
Human hemoglobin. Type IV, 100 mg/ml in the same buffer was 
reduced by excess sodiim dithionite, added to the column and eluted
The main band was collected and stored under
3
H-PQ was incubated for 60 minutes 
with the eluted hemoglobin (75 mg) and mouse liver microsomes (10 mg) 
in the presence or absence of an NADPH-generating system as described
NaCl.
with the same buffer.
(Summerfield and Tudhope, 1978).
62
above. The incubation mixtures were transferred to ultracentrifuge 
tubes at the end of the incubation. The tubes were centrifuged at
105,000 x g for 30 minutes in a Beckman Model L3-50 ultracentrifuge. 
The microsome free supernatant was placed on the Sephadex G-75 column
and eluted with 0.05 M pH 7.8 phosphate buffer containing 0.15 M NaCl.
The effluent was monitored at 280 nm and fractions were collected. An
aliquot of 100 ul of each fraction was added to 10 ml CytoScint cock­
tail and counted for radioactivity.
Methemoglobin Formation and Assay
PQ, 5H6DPQ and the blue derivative of 5H6DPQ were incubated with
0.5 ml of a 50% normal or G6PD-deficient erythrocyte suspension at 
37°C for 60 minutes in a Dubnoff shaking incubator, 
buffer (0.25 M, pH 7/35) was added to the incubation mixtures to bring
Sufficient Tris
the final volume to 1.75 ml. The flasks were placed in ice for 5
minutes at the end of the incubation and the contents then transferred
The tubes were centrifuged at 1000 x g for 10to centrifuge tubes.
minutes. The supernatant was aspirated and the packed erythrocytes
were washed twice with 2.0 ml 0.85% buffered saline containing 10 mM
dextrose. An aliquot of 0.1 ml of the resuspended 50% erythrocytes 
suspension in the above buffer was used for methemoglobin assay as 
described by Fraser and Vesell (1968a). In some experiments 
a-tocopherol in absolute ethanol was added to the incubation mixture 
to study its effects on methemoglobin formation by 5H6DPQ.
Mice were injected with PQ (80 mg/Kg, i.p.) and sacrificed by 
cervical dislocation at various times after PQ administration. Blood
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was collected by cardiac puncture with heparin as anticoagulant. The
blood was centrifuged at 1000 x g for 10 minutes. The packed 
erythrocytes were washed with 0.85% buffered saline containing 10 mM
dextrose and methemoglobin assays were performed as described above.
Effects of Primaquine and Its Metabolites on Normal and G6PD-
Deficient Erythrocyte Membrane Sulfhydryl Levels
PQ, 5H6DPQ, or the blue derivative of 5H6DPQ was incubated with 
4.0 ml of normal or G6PD-deficient red blood cells (50% suspension). 
A sufficient volume of 0.25 M Tris buffer, pH 7.35 was added to
Incubationbring the final volume of incubation mixtures to 5.0 ml.
was carried out at 37°C under air for 60 minutes in a Dubnoff shaking
Incubation flasks were kept in ice for 5 minutes at theincubator.
end of the incubation. The incubation mixtures were then transferred
to centrifuge tubes and centrifuged at 1000 x g for 10 minutes. The 
supernatant was aspirated and the packed erythrocytes were lysed with
40 ml of cold 4 mM Na phosphate buffer, pH 8.0, and ghosts were 
prepared by the method of Fairbanks et al. (1971). The ghosts were
resuspended in 0.5 ml of 0.02 M disodiun EDTA and a sufficient volume
of the same sodium phosphate buffer up to the original volume of the 
packed cells. An aliquot of the ghost suspension (0.4 ml) was mixed
with 4.55 ml of 0.01 M sodi un phosphate buffer (pH 8.0) and 0.05 ml of
0.01 M DTNB in absolute methanol. The solution was kept in the dark 
at room temperature for 50 minutes and then centrifuged at 17,000 x g 
for 5 minutes (Szeinberg and Clejan, 1964).
was measured against both a reagent blank (no tissue) and a tissue




Data were expressed as the mean ± S.E.M. The significance of the 
difference between means was determined by Student's t-test. Statis­
tical differences were considered to be significant when p < 0.05.
Results
Lipid Peroxidation and Covalent Binding in Microsomes
As expected, Table 10 shows that lipid peroxidation in mouse liver 
microsomes was markedly enhanced by the presence of the cofactor 
mixture which generated NADPH. 
marked decrease in lipid peroxidation indicating substrate inhibition 
of NADPH-induced microsomal lipid peroxidation as has been reported for 
other compounds (Miles et a_]_. , 1980).
peroxidation over 60 minutes in the presence of 0.1 mM PQ, 5H6DPQ or 
the blue derivative of 5H6DPQ was examined with the results shown in
When 0.1 mM PQ was added there was a
The time course of lipid
Figure 9; zero time values were subtracted from those at all other
incubation intervals. Most of the lipid peroxidation occurred in the
first 15 minutes; following this period the results were quite varia­
ble except for a steady increase in lipid peroxidation with 5H6DPQ in
the presence of cofactors. Overall, 5H6DPQ was the most active in
producing lipid peroxidation while its blue derivative was the least 
active; in all cases the effect was greater in the presence of NADPH
generated by the cofactor mixture.
Addition of a-tocopherol (0.01 mM) produced more than a 50% 
inhibition of lipid peroxidation in the presence of primaquine and
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cofactors as shown in Table 11. The results of a comparable study of 
the effect of a-tocopherol on the covalent binding of tritiated PQ to 
mouse liver microsomal protein are shown in Table 12. There was a 30% 
inhibition of covalent binding when a-tocopherol in absolute alcohol 
was added to the incubation mixture in the binding studies, whereas 
the inhibition effect contributed by absolute ethanol alone was only 
10%. It appears that a-tocopherol inhibited lipid peroxidation in the
presence of PQ significantly more than it inhibited the covalent bind­
ing of PQ.
Lipid Peroxidation in Erythrocytes
As shown in Table 12, considerable lipid peroxidation occurred in 
intact erythrocytes incubated for 60 minutes;, addition of the cofactor
mixture produced a small increase in the amount of peroxidation. When
PQ was added in the absence of cofactors there was much less lipid
peroxidation than in the control; addition of cofactors removed this
inhibitory effect of PQ so that peroxidation was now a little greater
than in the control with cofactors. Quite similar results were
obtained with 5H6DPQ and the blue derivative from 5H6DPQ, although
they were less inhibitory to lipid peroxidation in the absence of
cofactors.
The results of a study of the time course of lipid peroxidation 
in human erythrocyte membranes in the presence of 5H6DPQ and with and 
without cofactors are shown in Figure 10. 5H6DPQ significantly 
inhibited the NADPH-induced lipid peroxidation in erythrocyte mem­
branes in contrast to the lack of such inhibition in intact erythrocytes.
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Methemoglobin (metHb) Formation in Erythrocytes
As reported previously (Strother et _al_. , 1981, 1983), low (0.1- 
0.005 mM) concentrations of 5H6DPQ readily oxidize Hb to metHb in both
normal and G6PD-deficient erythrocytes. A comparison of metHb forma­
tion by 0.1 mM PQ, 5H6DPQ and the blue derivative of 5H6DPQ in normal 
and G6PD-deficient human erythrocytes after a sixty minute incubation 
is shown in Table 14. 5H6DPQ was much more active than PQ or the blue 
derivative and produced si gni fi cantly more metHb in G6PD-defi cient 
than in normal erythrocytes. In contrast to its effect on lipid 
peroxidation and covalent binding, a-tocopherol did not inhibit met­
hemoglobi n formation by 5H6DPQ in normal erythrocytes (Table 15).
Covalent Binding in Erythrocytes
In Table 16 are shown the results of studies on the covalent 
binding of 0.01 mM ^H-PQ to total protein of both normal and G6PD-
defi cient erythrocytes incubated with mouse liver microsomes with and
without the cofactor mixture present. There was a significant net
Also the netbinding attributable to the presence of the cofactors, 
binding to the protein of G6PD-deficient cells was significantly
greater than that to normal erythrocytes.
The possibility that PQ or its metabolites may bind covalently
to the proteins of erythrocyte membranes was examined by incubating
30.01 or 0.1 mM H-PQ with mouse hepatic microsomes and human erythro­
cyte membranes in the presence or absence of the cofactor mixture. It
was not possible to separate the microsomes from the erythrocyte
membranes after the incubation so that it was only possible to measure
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the total covalent binding to the combined microsomal and membrane 
protein. At both concentrations of PQ the net binding to the combined 
microsomal-membrane protein (attributable to the presence of cofactors) 
was significantly greater than that when PQ was incubated with mouse 
liver microsomes alone (Table 17). These results suggest that there 
was small but significant amount of primaquine metabolite(s) bound to 
human erythrocyte membrane proteins.
Since covalent binding to membranes could involve -SH groups, the
effect of 0.1 mM PQ, 5H6DPQ or the blue derivative of 5H6DPQ on the
-SH groups of normal and G6PD-defi ci ent erythrocyte membranes was 
measured. Table 18 shows that all three compounds significantly 
decreased the amount of measurable sulfhydryl groups of G6PD-deficient 
human erythrocyte membranes but had no effect on normal erythrocyte 
membranes. The effect of 5H6DPQ was more marked than that of PQ or
the blue derivative of 5H6DPQ.
The possibility that PQ or its metabolites may bind covalently to 
hemoglobin was examined by incubating human hemoglobin (Type IV) with
o
H-PQ and mouse liver microsomes as described under "Methods." As 
shown in Table 19 and Figures 11 and 12, after separation on a Sephadex 
G-75-40 column, a significant amount of radioactivity was found in the 
fractions from the incubation mixture containing cofactors which was 
significantly greater than that from the incubation mixture lacking 
cofactors. The radioactive peaks B and C of Figures 3 and 4 appear to
3
be due to H-PQ and breakdown products or metabolites of PQ; they were
3
also observed when H-PQ was chromatographed in 0.25 M Tris buffer on
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the Sephadex G-75-40 column without prior incubation, 
absorbance peak at 280 nm from fractions 35 to 47 in Figure 12 may be 
attributable to primaquine metabolite(s) since model metabolites of 
primaquine did show some absorbance at that wavelength.
Also the small
Oxidation of Hemoglobin in vivo
Table 20 shows that there is no significant amount of methemo- 
globin produced in vivo after injection of 80 mg/Kg of PQ.
Discussion
Although PQ has been found to produce reactive oxygen species 
(Cohen and Hochstein, 1964; Summerfield and Tudhope, 1978; Fraser et 
al_. , 1981) and the 5 ,6-di hydroxy derivative (5H6DPQ) may react with 
oxygen to produce hydrogen peroxide (Fraser ^t al., 1981) they did 
not stimulate NADPH-dependent microsomal lipid peroxidation in this 
study.
inhibited NADPH-induced microsomal lipid peroxidation markedly.
In fact, PQ, 5H6DPQ, and the blue derivative from 5H6DPQ
Many investigators have reported substrate inhibition of NADPH- 
induced microsomal lipid peroxidation (Orreni us el: jil_. , 1964; Pederson 
and Aust, 1974; Miles, 1980) but suggested different mechanisms.
Orreni us et a/L (1964) proposed that the inhibition is due to a compe­
tition between drug metabolism and lipid peroxidation for reducing 
equivalents derived from NADPH. Pederson and Aust (1974) concluded 
that the inhibition of lipid peroxidation is caused by the antioxidant 
properties of a drug metabolite which is formed in the presence of
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Miles et_ a]_. (1980) believe that inhibition of hepatic micro­
somal lipid peroxidation is independent of drug metabolism but is 
caused by the antioxidant properties of the substrates, 
be metabolized rapidly in the body (Tarlov et al_. , 1962) and has oxidant 
and redox properties (Flanagan et al_. , 1958; Tarlov et al_., 1962).
It seems likely that the inhibitory effect of PQ and its derivatives 
on hepatic microsomal lipid peroxidation is due to the competition 
between drug metabolism and lipid peroxidation for NADPH-reduci ng equi-
NADPH.
PQ is known to
valents.
On the other hand, Anundi et aj_. (1979) and Smith et al. (1983)
found that bromobenzene also shows some degree of substrate inhibition
of lipid peroxidation and they suggested that the lipid peroxidation 
which occurs during bromobenzene toxicity is due to the depletion of 
GSH and is a consequence of cell death.
The small amount of NADPH-induced lipid peroxidation in the 
presence of PQ is reduced by a-tocopherol to less than 50%. 
a-Tocopherol is a well known antioxidant and radical scavenger, 
interrupts the free radical chain reactions of lipid peroxidation
It
(Bus and Gibson, 1979; Chance et aj_., 1979).
The inhibition of covalent binding of PQ metaboli te (s) to mouse
liver microsomal protein by a-tocopherol is probably due to its 
antioxidant effect which spared hepatic GSH from oxidation and thus 
protect tissue macromolecules against electrophilic attack by PQ 
reactive metabolite(s).
Substrate inhibition of NADPH-dependent lipid peroxidation was
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also found in human erythrocytes and erythrocyte membranes in the 
presence of PQ, 5H6DPQ and the blue derivative of 5H6DPQ. In order to 
ensure the presence of sufficient reducing equivalents, an NADPH- 
generating system was added to human intact erythrocytes and 
erythrocytes membranes in lipid peroxidation studies. The addition of 
cofactors to intact red cells (Table 13) may enhance the redox cycling
reaction between oxyhemoglobin and PQ as well as its derivatives,
increase reactive oxygen species production, and thus potentiate lipid
peroxidation.
5H6DPQ is more active in producing methemoglobin in vitro than PQ 
and the blue derivative from 5H6DPQ, especially in G6PD-deficient red 
cells as reported by Strother et aj_. (1981, 1983). This result 
indicates that a PQ metabolite(s) is more potent than PQ itself in 
inducing toxicity. G6PD-deficient cells are more vulnerable than 
normal cells to oxidative damage. Even though PQ can deplete hepatic 
and erythrocyte GSH contents as reported previously (Chau et al. ,
1983) it does not produce a significant amount of methemoglobi n in 
vivo. In contrast to its effect on lipid peroxidation and covalent
binding, a-tocopherol does not inhibit in vitro methemoglobi n forma­
tion by 5H6DPQ in normal red cells.
The fact that PQ metabolite(s) decreased sulfhydryl groups of 
G6PD-deficient human erythrocyte membranes significantly but had no 
effect on those of normal red cell membranes suggests that covalent 
binding may be one of the mechanism of PQ-induced hemolysis, 
results of other studies in our laboratory (unpublished data) with
The
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5H6DPQ and its blue derivative, show a dose-related decrease of GSH
contents of G6PD-deficient erythrocytes but not of normal cells. 
Flanagal et ail_. (1958) have also found that an acute destruction of 
GSH precedes hemolysis in PQ-sensitive subjects. Further evidence is 
provided by the fact that the PQ metabolite(s) binds to human 
erythrocyte total protein, hemoglobin and plasma membrane protein 
covalently. G6PD-deficient erythrocytes are more prone to covalent 
binding. Furthermore, Beutler et aj_. (1957) and Tarlov et a]_ (1962) 
did not find an equivalent rise in oxidized glutathione (GSSG) to the 
fall in GSH. Beutler et _a]_. (1957) suggested that GSSG may change to 
hydrogen sulfide eventually, and Tarlov et al_. (1962) explained that 
there may be a formation of mixed sulfides of GSH with sulfhydryl 
groups of the globin molecule. We suggest that the decrease of GSH 
may be due to covalent binding in addition to oxidation.
A recent study of Kelman et _al_. (1982) indicated that PQ lowers 
cellular NADPH level but not GSH content, and stimulate the hexose
monophosphate shunt in normal human erythrocytes. These investigators 
agree with Cohen and Hochstein (1964) that PQ mediates H^O^ formation, 
in oxyhemoglobin-containing red cells and PQ reacts with NADPH to 
produce H^.
In normal red cells, the activity of G6PD is increased by the 
decreased NADPH levels, which is either lowered by direct interaction 
with PQ (Kelman .et a/L , 1982) or by consimption in glutathione 
reductase reactions to reduce GSSG or peroxides (Cohen and Hochstein, 
1964), or by the combination of both reactions, and thus glucose-6-
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phosphate is oxidized at a higher rate to regenerate an adequate
In G6PD-deficient erythrocytes, as the hexose 
monophosphate pathway activity is diminished, adequate NADPH levels
amount of NADPH.
cannot be maintained under oxidative stress.
The result of this study and others suggest the following sequence
(1) Cellular GHS content isof events leading to PQ induced hemolysis: 
depleted by PQ metabolite(s) and reactive oxygen species produced from
(2) The G6PD-PQ through covalent binding, conjugation, or oxidation, 
deficient erythrocytes are incapable of maintaining an adequate amount
of NADPH for the reduction of GSSG and mixed disulfide of GSH and
protein to regenerate GSH by way of the glutathione reductase reaction. 
GSH is important in maintaining the sulfhydryl groups of red cell 
enzymes and membranes in the reduced state (Beutler, 1978), and in 
removing the harmful hydrogen peroxide and organic peroxides in erythro­
cytes. The GSH depletion renders the red cell membranes susceptible to 
oxidative change and red cell enzymes to inactivation. (3) PQ 
metabolite(s) oxidize(s) and binds to vital red cell membrane proteins, 
hemoglobin, and enzymes after the protective role of GSH is decreased. 
(4) Red cell membrane permeability is then changed (Weed, 1961), enzyme 
functions are altered or destroyed and eventually the lysis of erythro­
cytes occurs (Beutler, 1954).
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Table 10. Effect of 0.1 mM primaquine (PQ) and cofactors (CM) on lipid
peroxidation in mouse hepatic microsomes
nmoles malondialdehyde 
equivalent/mg microsomal protein5
60 mi n-0 mi n.0 minutes 60 minutesCondition
6.22 ± 0.65 
51.33 ± 6.50b 
1.62 ± 0.35 
2.11 ± 0.35c
0.78 ± 0.20 7.00 ± 0.79Microsome
Microsome + CM 0.85 ± 0.03 52.17 ± 6.50
0.79 ± 0.08 2.41 ± 0.19Microsome + PQ
2.88 ± 0.330.79 ± 0.06Microsome + PQ + CM
aValues shown are means and standard errors for 3 to 7 experiments. 
bSi gnificantly different from microsome incubated without CM at
p < 0.001
Significantly different from microsome incubated with CM at
p < 0.001
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Table 11. Effect of 0.01 mM a-tocopherol on lipid peroxidation in mouse 
liver microsomes by 0.01 mM primaquine (PQ) in the presence or absence 
of cofactors (CM)
nmoles malondialdehyde equivalent/mg 
microsomal protein5
No CofactorsDrug With Cofactors
PQ (control) 0.94 ± 0.26 8.06 ± 0.37
PQ + a-tocopherol in absolute 
ethanol 3.44 ± 0.65b 
9.80 ± 0. 48C
0.53 ± 0.17
PQ + absolute ethanol 1.18 ± 0.35
aValues shown are means and standard errors for 4 experiments. Zero 
time values was subtracted from values at 60 minutes of incubation.
^Significantly different from control with CM at p < 0.005
Significantly different from control with CM at p < 0.025
3 3Effect of 0.01 mM a-tocopherol on covalent binding of 0.01 mM H-primaquine ( H-PQ) toTable 12.
mouse liver microsomal protein in vitro in the presence or absence of cofactors
nmoles bound/mg protein/60 minutes5
Net Bound % InhibitionNo Cofactors With CofactorsDrug
^H-PQ (control)
3
H-PQ + a-tocopherol in 
absolute ethanol
^H-PQ + absolute ethanol
0.05 ± 0.01 0.26 ± 0.001 0.21 ± 0.01
0.15 ± 0.01b 
0.19 ± 0.003c
0.04 ± 0.004 0.19 ± 0.01 30%
0.04 ± 0.004 0.24 ± 0.004 10%
Values shown are means and standard errors for 3 to 4 experiments. 
bSignificantly different from control at p < 0.005 




Table 13. Lipid peroxidation of human erythrocytes by primaquine
and its model metabolites
nmoles malondialdehyde equivalent/qm Hba
With CofactorsNo CofactorsDrug
None (control) 50.8 ± 17.4 74.0 ± 11.5
84.1 ± 31.221.9 ± 5.00.1 mM PQ
39.7 ± 15.6 79.4 ± 27.00.1 mM 5H6DPQ
0.1 mM blue compound from 
5H6DPQ 91.4 ± 8.336.5 ± 9.3
aValues shown are means and standard errors for 4 experiments. Zero 
time values were subtracted from values at 60 minutes of incubation.
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Table 14. Effect of 0.1 mM primaquine, 5H6DPQ and blue compound
from 5H6DPQ on methemoglobin formation of normal and G6PD-deficient
erythrocytes i_n vitro
Percent methemoglobina
Normal RBC G6PD deficient RBCDrug
None (control) 2.1 ± 0.7 





5.7 ± 0.8 5.6 ± 0.8Blue compound from 
5H6DPQ
aValues shown are means and standard errors for 4 experiments. 
^Significantly different from normal RBC at p < 0.05 
Significantly different from normal RBC at p < 0.005
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Table 15. Effect of 0.01 mM a-tocopherol on methemoglobin
formation by 0.1 mM 5H6DPQ in vitro
Percent methemoglobinaDrug
None (control) 2.2 ± 0.4 
12.4 ± 0.8b5H6DPQ
5H6DPQ + a-tocopherol in 
absolute ethanol 13.5 ± 0.6b 
12.0 ± 1.0b5H6DPQ + absolute ethanol
aValues shown are means and standard errors for 4 experi­
ments.
^Significantly different from control at p < 0.001
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Table 16. Covalent binding of 0.01 mM H-primaquine to normal and 
G6PD-deficient human erythrocyte protein in vitro
pmoles bound/mg human RBC protein5
Net BoundWith CofactorsNo CofactorsRBC
5.2 ± 0.5 
9.0 ± 1.9b
7.1 ± 2.2 12.3 ± 2.3Normal
17.6 ± 2.68.6 ± 0.7G6PD-defi ci ent
aValues shown are means and standard errors for 3 to 4 experiments. 
bSignificantly different from normal RBC at p < 0.05
3
Covalent binding of H-Primaquine to mouse liver microsomal protein and hunan 
erythrocyte membrane j_n vi tro
Table 17.
nmoles bound/mg microsomal protein/4 mg RBC membrane3
3H-PQ Cone. Net BoundWith CofactorsNo CofactorsCondi ti on
Microsome (control) 0.50 ± 0.03 1.07 ± 0.06 0.57 ± 0.03 
0.69 ± 0.04b 
0.16 ± 0.01 
0.20 ± 0.02c
0.1 mM
0.46 ± 0.02 1.15 ± 0.020.1 mMMicrosome + RBC membrane
Microsome (control) 0.20 ± 0.0010.01 mM 0.05 ± 0.01
0.05 ± 0.003 0.25 ± 0.010.01 mMMicrosome + RBC membrane
aValues shown are means and standard errors for 3 to 4 experiments. 
^Significantly different from control (0.1 mM) at p < 0.05 
cSignificantly different from control (0.01 mM) at p < 0.05
oo
o
Table 18. Effect of 0.1 mM primaquine, 5H6DPQ, and blue compound from 5H6DPQ on
sulfhydryl groups of normal and G6PD-deficient human erythrocyte membrane in vitro
-SH groups, mg/gm human RBC membrane protein
G6PD-defi cient RBC
I NormalNormal RBC Membrane membraneDrug
None (control) 75%13.3 ± 1.0 9.7 ± 1.6 
8.3 ± 1.5b 
6. 9 ± 0. 9C 
8.1 ± 1.6d
69%12.1 ± 0.9PQ
54%5H6DPQ 12.8 ± 1.2
66%Blue compound from 5H6DPQ 12.2 ± 0.8
aValues shown are means and standard errors for 4 to 5 experiments.
Significantly different from normal at p < 0.05
Significantly different from normal at p < 0.001





Table 19. Covalent binding of 0.01 mM H-primaquine 
to human hemoglobin (Type IV) in vitro
nmoles bound/mg hemoglobin/30 minutes5
Net BoundNo Cofactors With Cofactors
0.062 ± 0.003b 0.024 ± 0.0030.038 ± 0.006
aValues shown are means and standard errors for 3 
experiments.
Significantly different from binding without cofactors 
at p < 0.025
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Effect of 80 mg/Kg of primaquine on methemo- 
globin formation in vivo
Table 20.
Percent methemoglobinaHours after PQ injection
1.6 ± 0.50
0.5 3.6 ± 0.1
0.9 ± 0.31
2.2 ± 0.52
4 1.1 ± 0.1
8 2.7 ± 0.1
aValues shown are the mean and standard error for 4 animals.
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Figure 9. Time course of effect of 0.1 mM primaquine, 5H6DPQ, and blue 
compound from 5H6DPQ on lipid peroxidation of mouse liver microsomes in 
vitro. Each point is mean and standard error for 3 to 6 experiments.
A, primaquine; ▲—
-■ , 5H6DPQ + CM; o 
t, blue compound from 5H6DPQ + CM.
A, primaquine + CM; □
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Figure 10. Time course of lipid peroxidation of human erythrocyte 
membrane. Each point is mean and standard error of 3 experiments.
RBC membrane + CM;
□, RBC membrane + 0.1 mM 5H6DPQ; ■■
+ 0.1 mM 5H6DPQ + CM.
CM at p < 0.025.
0 0, RBC membrane; »
■* , RBC membrane 





































Figure 11. Column chromatography of human hemoglobin (Type IV) on 
Sephadex G-75-40 gel after incubated with 0.01 mM ^H-primaquine and 
mouse liver microsomes i_n vitro. All fractions were counted for radio-
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Figure 12. Column chromatography of human hemoglobin (Type IV) on 
Sephadex G-75-40 gel after incubated with 0.01 mM ^H-primaquine, mouse 
liver microsomes, and cofactors in vitro. All fractions were counted 
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